Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06176079

Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease

Sponsor: Michael Ohliger, MD PhD

View on ClinicalTrials.gov

Summary

The recent development of dissolution dynamic nuclear polarization (DNP) technology for hyperpolarized (HP) 13C imaging offers a promising new avenue for non-invasively accessing fundamental metabolic changes associated with the progression of fatty liver disease in vivo. The purpose of this pilot study is to optimize sequence parameters for hyperpolarized 13C acquisition in the human liver and determine which metabolic changes can be seen in humans with simple, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) when compared to healthy volunteers.

Official title: Pilot Study of Magnetic Resonance Imaging With Hyperpolarized Pyruvate (13C) In Patients With Fatty Liver Disease

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

44

Start Date

2020-07-22

Completion Date

2025-08-28

Last Updated

2026-08-03

Healthy Volunteers

Yes

Interventions

DRUG

Hyperpolarized (HP) 13C

A dosage of 0.43 mL/kg body weight at the maximum dosage will be injected intravenously at a rate of 5 mL/second.

DRUG

Hyperpolarized 13C-Urea

Given intravenously (IV)

PROCEDURE

Magnetic Resonance Imaging

Imaging procedure

PROCEDURE

Saline Flush

A 20 milliliter (mL) saline flush at 5 mL/second will be given after each dose of HP 13C

Locations (1)

University of California, San Francisco

San Francisco, California, United States